期刊文献+

非布司他治疗痛风及高尿酸血症的临床疗效及其安全性 被引量:2

下载PDF
导出
摘要 目的探讨非布司他治疗痛风及高尿酸血症的临床疗效及其安全性。方法选取孝昌县第一人民医院2015年5月-2018年1月收治的痛风及高尿酸血症患者200例,按照随机数字表法分为观察组与对照组,各100例。对照组患者予以别嘌醇治疗,观察组患者予以非布司他治疗。比较两组患者治疗前后血尿酸水平,并观察两组患者不良反应情况。结果治疗前两组患者血尿酸水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血尿酸水平低于对照组(P<0.05)。观察组患者不良反应发生率低于对照组(P<0.05)。结论非布司他治疗痛风及高尿酸血症可有效降低患者血尿酸水平,且安全性较高。
作者 吕庆芳
出处 《临床合理用药杂志》 2019年第15期85-86,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献8

二级参考文献52

  • 1Terkeltauh R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics [J]. Arthritis Res Ther, 2006, 8( Suppl 1) : S4.
  • 2Chao 1, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout [J]. CUff Rheumatol Rep, 2009,11 (2): 135-140.
  • 3Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout [J]. Cochrane Database Syst Rev, 2012, 14 (1):11.
  • 4Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase ill , randomized, double-blind, parallel-group trial [J]. Arthritis Rheum, 2008,59(11):1540-1548.
  • 5Schumacher HR, Becker MA, Lioyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study [J]. Rheumatology(Oxford), 2009,48(2): 188-194.
  • 6El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease? [J]. Cleve Clin J Med, 2010,77(12):919-928.
  • 7Ernst ME, Fravel MA. Febuxostat , a selective xanthine-oxidase/ xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout [J]. Clin Ther, 2009, 31 ( 11 ) : 2503-2518.
  • 8Ye P, Yang SM, Zhang WL, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis [J]. Clin Ther, 2013 , 35 (2): 180-189.
  • 9Becker MA, Schumacher HR Jr , Espinoza L, et al. A phase 3 randomized, controlled, multicenter, double-blind trial (RCT) comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout [J]. Arthritis Rheum, 2008,58(suppI9) :L11.
  • 10Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the Standing Committee for international Clinical Studies Including Therapeutics (ESCISIT) [J]. Ann Rheum Dis, 2006, 65( 10): 1312-1324.

共引文献290

同被引文献25

引证文献2

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部